WO2009030770A2 - Procédés et outils de diagnostic de cancer chez des patients er- - Google Patents

Procédés et outils de diagnostic de cancer chez des patients er- Download PDF

Info

Publication number
WO2009030770A2
WO2009030770A2 PCT/EP2008/061828 EP2008061828W WO2009030770A2 WO 2009030770 A2 WO2009030770 A2 WO 2009030770A2 EP 2008061828 W EP2008061828 W EP 2008061828W WO 2009030770 A2 WO2009030770 A2 WO 2009030770A2
Authority
WO
WIPO (PCT)
Prior art keywords
gene
genes
protein
proteins
kit
Prior art date
Application number
PCT/EP2008/061828
Other languages
English (en)
Other versions
WO2009030770A3 (fr
Inventor
Christos Sotiriou
Benjamin Haibe-Kains
Christine Desmedt
Original Assignee
Universite Libre De Bruxelles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Libre De Bruxelles filed Critical Universite Libre De Bruxelles
Priority to CA2696947A priority Critical patent/CA2696947A1/fr
Priority to EP08803797A priority patent/EP2185728A2/fr
Priority to JP2010523521A priority patent/JP2010537659A/ja
Priority to US12/733,574 priority patent/US20100298160A1/en
Priority to AU2008294687A priority patent/AU2008294687A1/en
Priority to BRPI0815460A priority patent/BRPI0815460A2/pt
Publication of WO2009030770A2 publication Critical patent/WO2009030770A2/fr
Publication of WO2009030770A3 publication Critical patent/WO2009030770A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Definitions

  • the present invention is related to methods and tools for obtaining an efficient prognosis (prognostic) of breast cancer estrogen receptor (ER)- patients, wherein the immune response is the key player of breast cancer prognosis .
  • CD4+ cells belong to the leukocyte family which is a major component of the breast tumor microenvironment .
  • CD4 marker is mainly expressed on helper T cells and with a limited level on monocyte/macrophages and dendritic cells. Immune cells play a role in tumor growth and spread, notably in breast tumor, and CD4+ cells are key players in the regulation of immune response.
  • breast cancer in addition to being a clinically heterogeneous disease, is also molecularly heterogeneous, with subgroups primarily defined by ER (ESRl), HER-2 (ERBB2) expression, the different prognostic signatures were never clearly evaluated and compared in these different molecular subgroups. This was probably due to the relatively small sizes of the individual studies, which would have made these findings statistically unstable.
  • ESRl ER
  • ERBB2 HER-2
  • the present invention aims to provide methods and tools that could be used for improving the diagnosis
  • the present invention aims to provide methods and tools which improved the prognosis (prognostic) of patient and do not present drawbacks of the state of the art but also are able to propose a prognostic of all patients presenting a predisposition to tumors especially breast tumors development, which means patients which are identified as ER- patients, but also ER+ patients and HER2+/ERBB2 patients.
  • the present invention is related to a gene/protein set that is selected from mammal (preferably human) immune response associated (or related) genes or proteins which are used for the prognosis (prognostic, detection, staging, predicting, occurrence, stage of aggressiveness, monitoring, prediction and possibly prevention) of cancer in ER- patients.
  • mammal preferably human
  • immune response associated (or related) genes or proteins which are used for the prognosis (prognostic, detection, staging, predicting, occurrence, stage of aggressiveness, monitoring, prediction and possibly prevention) of cancer in ER- patients.
  • genes which are associated with a human response in a mammal patient could be used for a specific and adequate diagnosis and prognosis of cancer in ER- patients.
  • These genes are highly expressed in tumor cells and/or in lymphocytes present in the biopsy of ER- patients. Therefore, these genes their corresponding encoded protein and antibodies or hypervariable portions thereof directed against these proteins could be used as key markers of this pathology in ER- patients.
  • a first aspect of the present invention is related to a gene or protein set comprising or consisting of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 and possibly 100, 105, 110 genes or protein or the entire set selected from the table 10 and/or table 11 and antibodies or hypervariable portions thereof that are specifically directed against their corresponding encoded proteins (possibly combined with one or more gene(s) of the set of genes as described by A. Teschendorff et al (genome biology nr 8,R157-2007 dedicated to efficient prognostic of cancer of ER- patient) .
  • the gene and protein sets according to the invention were selected from gene or proteins sequences or antibodies (or hypervariable portion thereof) directed against their encoded proteins that are bound to a solid support surface, preferably according to an array.
  • the present invention is also related to a diagnostic kit or device comprising the gene/protein set according to the invention possibly fixed upon a solid support surface according to an array and possibly other means for real time PCR analysis (by suitable primers which allows a specific amplification of 1 or more of these genes selected from the gene set) or protein analysis.
  • the solid support could be selected from the group consisting of nylon membrane, nitrocellulose membrane, polyvinylidene difluoride, glass slide, glass beads, polyustyrene plates, membranes on glass support, CD or DVD surface, silicon chip or gold chip.
  • these set means for real time PCR analyse are means for qRT-PCR of the genes of the gene set (especially expression analysis over or under expression of these genes) .
  • Another aspect of the present invention is related to a micro-array comprising one or more of the genes/proteins selected from the gene/protein set according to the invention, possibly combined with other gene/protein selected from other gene/protein sets for an efficient diagnosis (diagnostic) preferably prognosis (prognostic) of tumors, preferably breast tumors.
  • kits or devices which is preferably a computerized system comprising a bio assay module configured for detecting gene expression (or protein synthesis) from a tumor sample, preferably based upon the gene/protein sets according to the invention and - a processor module configured to calculate expression (over or under expression) of these genes (or synthesis of corresponding encoded proteins) and to generate a risk assessment for the tumor sample (risk assessment to develop a malignant tumor) .
  • the tumor sample is any type of tissue or cell sample obtained from a subject presenting a predisposition or a susceptibility to a tumor, preferably a breast tumor that could be collected (extracted) from the subject .
  • the subject could be any mammal subject, preferably a human patient and the sample could be obtained from tissues which are selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary track, thyroid cancer, renal cancer, carcinoma, melanoma or brain cancer preferably, the tumor sample is a breast tumor sample.
  • the gene set according to the invention could be combined, preferably in a diagnostic kit or device with other genes/proteins selected from other gene/protein sets preferably the gene/protein set(s) comprising or consisting of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, possibly 40, 45, 50, 55, 60, 65 genes or the entire set(s) of the gene/protein set(s) selected from table 12 and/or table 13 or antibodies and hypervariable portion thereof directed against their corresponding encoded proteins for an efficient prognosis (prognostic) of other types of breast cancer (HER 2+ , ERBB2, breast cancer type) .
  • prognostic prognostic
  • the gene set according to the invention comprises or consists of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 genes/proteins or the entire set selected from the genes/proteins designated as upregulated genes in grade 3 tumors in the table 3 of the document WO 2006/119593 or antibodies and hypervariable portion thereof directed against their corresponding encoded proteins.
  • these genes/proteins are proliferation related genes/proteins .
  • the gene/protein set comprises at least the genes/proteins selected from the group consisting of CCNBl, CCNA2, CDC2, CDC20, MCM2 , MYBL2, KPNA2 and STK6.
  • the selected genes/proteins are the 4 following genes/proteins CCNBl, CDC2, CDC20, MCM2 or more preferably CDC2, CDC20, MYBL2 and KPNA2 as described in the US CIP patent application serial n° 11/929043. These genes/proteins sequences are advantageously bound to a solid support as an array.
  • kit or device may also further comprise means for real time PCR analysis of these preferred genes, preferably these means for real time PCR are means for qRT- PCR and comprise at least 8 sequences of the primers sequences SEQ ID NO 1 to SEQ ID NO 16.
  • these gene/protein sets may also further comprise reference genes/proteins, preferably 4 references genes for real time PCR analysis, which are preferably selected from the group consisting of the genes TFRC, GUS, RPLPO and TBP.
  • These reference genes are identified by specific primers sequences, preferably the primers sequences selected from the group consisting of SEQ ID NO 17 to SEQ ID NO 24.
  • GGI gene expression grade index
  • RS relapse score
  • the person skilled in the art may also select one or more gene used for analysis differential gene expression associated with breast tumor as described in the document WO 2005/021788 especially the sequence of the gene ERBB2, GATA4, CDH15, GRB7, NRlDl, LTA, MAP2, K6, PKMl, PPARBP, PPPlRlB, RPL19, PSB3, LOC148696, NOL3, Ioc283849, ITGA2B, NFKBIE, PADI2, STAT3, OAS2, CDKL5, STAITGB3, MKI67, PBEF, FADS2, LOX, ITGA2, ESTA1878915/NA, JDPA, NATA, CELSR2, ESTN33243/NA, SCUBE2, ESTH29301/NA, FLJ10193, ESRA and other gene or protein sequence described in the gene set of this PCT patent application.
  • the kit or device according to the invention may therefore comprise 1, 2, 3 or more gene/protein sets preferably dedicated to each type of patient group (ER- patient group, ER2+ patient group and HER2+ patient group) and could be included in a system which is a computerized system comprising 1, 2 or 3 bio assay modules configured for gene expression (or protein synthesis) of 1 or more of these gene/protein sets for an efficient diagnosis (prognosis) of all types (ER+, ER-, HER2+)of breast cancer.
  • This system advantageously comprises one or more of the selected gene sets of the invention and a processor module configured to calculate a gene expression of this gene set(s) preferably a gene expression grade index (GGI) to generate a risk assessment for a selected tumor sample submitted to a diagnosis (diagnostic) .
  • GGI gene expression grade index
  • the molecules of the gene and protein set according to the invention are (directly or indirectly) labelled.
  • the label selected from the group consisting of radioactive, colorimetric, enzymatic, bioluminescent, chemoluminescent or fluorescent label for performing a detection, preferably by immunohistochemistry (IHC) analysis or any other methods well known by the person skilled in the art.
  • the present invention is also related to a method for the prognosis (prognostic) of cancer in a mammal subject preferably in a human patient preferably in at least ER- patient which comprises the step of collecting a tumor sample (preferably a breast tumor sample) from the mammal subject (preferably from the human patient) and measuring gene expression in the tumor sample by putting into contact sequences (especially mRNA sequences) with the gene/protein set according to the invention or the kit or device according to the invention and possibly generating a risk assessment for this tumor sample (preferably by designated the tumor sample as different subtypes within the ER- type and possibly in the ER+ and HER2+ types as being as higher risk and requiring a patient treatment regimen (for example adjusted to a specific chemotherapy treatment or specifically molecular targeted anti cancer therapy (such as immunotherapy or hormonotherapy) .
  • the invention is also useful for selecting appropriate doses and/or schedule of chemotherapeutics and/or (bio) pharmaceuticals, and/or targeted agents, among which one may cite Aromatase Inhibitors, Anti-estrogens, Taxanes, Antracyclines, CHOP or other drugs like Velcade TM , 5-Fluorouracil, Vinblastine, Gemcitabine, Methotrexate, Goserelin, Irinotecan, Thiotepa, Topotecan or Toremifene, anti-EGFR, anti-HER2/neu, anti- VEGF, RTK inhibitor, anti-VEGFR, GRH, anti-EGFR/VEGF, HER2/neu & EGF-R or anti-HER2.
  • Aromatase Inhibitors Aromatase Inhibitors, Anti-estrogens, Taxanes, Antracyclines, CHOP or other drugs like Velcade TM , 5-Fluorouracil, Vinblastine, Gemcitabine, Methotre
  • Another aspect of the present invention is related to a method for controlling the efficiency of a treated method or an active compound in cancer therapy.
  • the method and tools according to the invention that are applied for an efficient prognosis of cancer in various breast cancer patient types, could be also used for an efficient monitoring of treatment applied to the mammal subject (human patient) suffering from this cancer.
  • another aspect of the present invention is related to a method which comprises the prognosis (prognostic) method according to the invention before (and after) treatment of a mammal subject (human patient) with an efficient compound used in the treatment of subjects (patients) suffering from the diagnosis breast tumor.
  • This means that this method requires a (first) prognosis (prognostic) step which is applied to the patient, before submitting said subject (patient) to a treatment and a (second) diagnosis (diagnostic) step following this treatment.
  • the invention relates to the use of CDlO and/or PLAU signatures according to Tables 10 and/or 11 as diagnosis and/or to assist the choice of suitable medicine.
  • Another aspect of the present invention is related to a method for a screening of compounds used for their anti tumoral activities upon tumors especially breast tumor, wherein a sufficient amount of the compound (s) is administrated to a mammal subject
  • prognosis (prognostic) method is applied to said mammal subject before an administration of said active compound (s) and is applied following administration of said active compound (s) to identify, if the active compound (s) may modify the genetic profile (gene expression or protein synthesis) of the mammal subject.
  • a modification in the subject (patient) genetic profile means that the obtained tumor sample before or after administration of the active compound (s) has been modified and will result into a different gene expression (or protein synthesis) in the sample (that is detectable by the gene/protein set according to the invention) . Therefore, this method is applied to identify if the active compound is efficient in the treatment of said tumor, especially breast tumor in a mammal subject, especially in a human patient .
  • the active compound (s) which are submitted to this testing or screening method is recovered and is applied for an efficient treatment of mammal subject (human patient) .
  • Figure legends Figure 1 Dendrogram for clustering experiments, using centered correlation and average linkage.
  • Figure 2 Risk of metastasis among patients with subtype 1 breast cancer.
  • Figure 3 Risk of metastasis among patients with subtype 1 breast cancer.
  • Figure 4 represents joint distribution between the ER (ESRl) and HER2 (ERBB2) module scores for three example datasets: NKI2 (A), UNC (B), VDX (C) .
  • Clusters are identified by Gaussian mixture models with three components. The ellipses shown are the multivariate analogs of the standard deviations of the Gaussian of each cluster.
  • Figure 5 represents survival curves for untreated patients stratified by molecular subtypes ESR1-/ERBB2-, ERBB2+ and ESR1+/ERBB2- .
  • Figure 6 represents forest plots showing the log 2 hazard ratios (and 95% CI) of the univariate survival analyses in the global population (A) and in the ESR1-/ERBB2- (B) , the ERBB2+ (C) and in the ESR1+/ERBB2- (D) subgroups of untreated breast cancer patients.
  • Figure 7 represents Kaplan-Meier curves of the module scores which were significant in the univariate analysis in the molecular subgroup analysis.
  • the module scores were split according to their 33% and 66% quantiles.
  • STATl module in the ESR1-/ERBB2- subgroup (A) PLAU module in the ERBB2+ subgroup (B)
  • STATl module in the ERBB2+ module (C) STATl module in the ERBB2+ module
  • AURKA module in the ESR1+/ERBB2- subgroup (D) AURKA module in the ESR1+/ERBB2- subgroup
  • Figure 8 shows the Kaplan-meier survival curves for the ERB2+ subgroup of patients having low, intermediate and high scores for the combination of the tumor invasion and immune module scores.
  • INVESTIGATION OF THE IMMUNE RESPONSE BY STUDYING CD4+ CELLS The inventors have profiled CD4+ cells isolated from primary invasive ductal carcinomas. An unsupervised, hierarchical clustering algorithm allowed us to distinguish two groups of tumors which were different regarding the pathways involved in immune response. Considering these immune pathways, 111 genes that are differentially expressed in tumor infiltrating CD4+ cells were identified and they generated a gene signature called "CD4 infiltrating tumor signature" (CD4ITS) that differs substantially from previously reported gene signatures in breast cancer.
  • CD4ITS CD4 infiltrating tumor signature
  • CD4ITS The relationship between CD4ITS and clinical outcome in more than 2600 patients listed in public datasets was also analysed. An important finding was that the CD4ITS was associated with the risk of metastasis in patients with ER-negative breast carcinoma who are usually associated with the worst prognosis (prognostic) .
  • CD4+ cells were isolated form the unicellular suspension using Dynal® CD4 Positive Isolation Kit according to the manufacturer's instructions. The purity of the population was checked by flow cytometry.
  • RNA pellet was washed twice with 75% ethanol, dried using Speedvack, and resuspended in nuclease-free water. The amount and the quality of RNA were respectively determined using the Nanodrop and the Agilent Capiler System.
  • RNA 10 patient's breast carcinomas with a sufficient amount of good quality RNA were isolated from purified CD4+ cells infiltrating primary tumour.
  • Micro-array analysis was performed with Affymetrix U133Plus Genechips (Affymetrix) .
  • RNA two-cycle amplification, hybridation and scanning were done according to standard Affymetrix protocols.
  • Image analysis and probe quantification was performed with the Affymetrix software that produced raw probe intensity data in the Affymetrix CEL files.
  • the program RMA was used to normalise the data.
  • Statistical analysis Considering the 10 expression profiles of CD4+ cells isolated from invasive ductal carcinomas, an unsupervised, hierarchical clustering was established. On the basis of the BioCarta pathways, the difference between the clusters was analysed.
  • CD4ITSI CD4ITS index
  • CD4ITS Localisation CD4+ - Thl/Th2 - Generation of the CD4+ infiltrating tumor signature
  • Table 1 represents the classification of the genes included in the CD4ITS signature
  • CD4ITS CD4+ infiltrating tumor signature
  • Table 2 presents the 108 genes selected according to the criteria and composing the CD4ITS.
  • the prognostic value of the CD4IS on treated and untreated patients with subtype 1 breast cancer was investigated.
  • CD4ITS and other prognostic signatures.
  • the inventors have compared CD4ITS to the published predictive signatures, namely Wound 12 IGS 13
  • Hybridization probes were mapped to Entrez GeneID [19] through sequence alignment against RefSeq mRNA in the (NM) subset, similar to the approach by Shi et al. [20], using RefSeq version 21 (2007.01.21) and Entrez database version 2007.01.21. When multiple probes were mapped to the same GeneID, the one with the highest variance in a particular dataset was selected to represent the GeneID.
  • the inventors have considered a set of prototypes, i.e. genes known to be related to specific biological processes in breast cancer (BC) and aimed to identify the genes that are specifically co-expressed with each of them.
  • the inventors computed for each gene the direct and the combined associations.
  • the direct association is defined as the linear correlation between gene i and each prototype j separately
  • the combined association is defined as the linear correlation between gene i and the best linear combination of prototypes, as identified by feature selection (orthogonal Gram-Schmidt feature selection [21]) .
  • feature selection orthogonal Gram-Schmidt feature selection [21]
  • a model was considered as significantly better than another one if the combined p- value ⁇ 0.05. Because of computational limitation, we were not able to test all possible combinations of prototypes to predict gene i. Only the best set of prototypes with respect to mean squared LOOCV error of the corresponding multivariate linear model was identified using the orthogonal Gram-Schmidt feature selection [Chen et al . , 1989; 21] . This multivariate model was used in addition to the set of univariate models.
  • Gene i was identified to be specific to prototype j and was included in the module, also called gene list, j .
  • x- is the expression of a gene in the module that is present in the dataset' s platform
  • w ⁇ is either +1 or -1 depending on the sign of the association with the prototypes.
  • Robust scaling was performed on each module score to have the interquartile range equals to 1 and the median equals to 0 within each dataset, allowing for comparison between module scores.
  • Gene ontology and functional analysis were executed using Ingenuity Pathways Analysis tools (Ingenuity Systems, Mountain View, CA www.ingenuity.com ), a web-delivered application that enables the discovery, visualization, and exploration of molecular interaction networks in gene expression data.
  • the inventors clustered the tumors using the ER (ESRl) and HER2 (ERBB2) module scores by fitting Gaussian mixture models [23] with equal and diagonal variance for all clusters.
  • the inventors have used the Bayesian Information Criterion [24] to test the number of components. Each tumor was automatically classified to one of the identified molecular subgroups using the maximum posterior probability of membership in the clusters.
  • association analysis [0064] The inventors have estimated the pairwise correlation of the module scores using Pearson' s correlation coefficient. Each correlation coefficient was estimated for each dataset separately and combined with inverse variance-weighted method with fixed effect model [25] . Additionally, the inventors have tested the association between module scores and subtypes using Kruskal-Wallis test. The inventors have tested the association between module scores and clinical variables using Wilcoxon rank sum test. Each statistical test was applied for each dataset separately and p-values were combined using the inverse normal method with fixed effect model [29] . These association analyses were carried out both in the global population and in the different molecular subgroups.
  • the inventors have considered the relapse- free survival (RFS) of untreated patients as the survival endpoint.
  • RFS relapse- free survival
  • DMFS distant metastasis free survival
  • All the survival data were censored at 10 years.
  • Survival curves were based on Kaplan-Meier estimates, with the Greenwood method for computing the 95% confidence intervals.
  • Hazard ratios between two or three groups were calculated using Cox regression with the dataset as stratum indicator, thus allowing for different baseline hazard functions between cohorts.
  • the hazard ratios were estimated for each dataset separately and combined with inverse variance-weighted method with fixed effect model [25] .
  • the inventors have used a forward stepwise feature selection in a meta-analytical framework to identify the best multivariable Cox models.
  • the significance thresholds regarding the combined p-values (WaId test for hazard ratio) for the inclusion of a new feature (variable) and for the exclusion of a previously selected feature (variable) were set to 0.05.
  • AURKA also known as STK6, 7 or 15
  • PLAU also known as uPA
  • STATl VEGF
  • CASP3, ER ESRl
  • HER2 HER2
  • the ER (ESRl) module was composed of 469 genes and as expected characterized by the co-expression of several luminal and basal genes already reported by previous micro-array studies such as XBPl, TFFl, TFF3, MYB, GATA3, PGR and several keratins. Information was found in the IPKB for 326 of these genes and 139 were significantly associated with a particular function such as small molecule biochemistry, cancer-related functions, lipid metabolism, cellular movement, cellular growth and proliferation or cell death.
  • the HER2 (ERBB2) module included 28 genes, with nearly half of them co-located on the 17qll-22 amplicon, such as THRA, ITGA3 and PNMT.
  • the proliferation module included 229 genes, with 34 of them represented in the previously reported genomic grade index. One hundred forty-three genes matched the IPKB, out of which 93 were significantly associated with a particular function. As expected, the majority of these genes, such as CCNBl, CCNB2, BIRC5, were involved in cellular growth and proliferation, cancer and cell cycle related functions.
  • the tumor invasion/metastasis module included 68 genes with several metalloproteinases among them.
  • the immune response module included 95 genes and the functional analysis carried out on 82 of them revealed that the majority was associated with immune response, followed by cellular growth and proliferation, cell-signaling and cell death.
  • the angiogenesis module included 10 genes related with cancer, gene expression, lipid metabolism and small molecule biochemistry and finally the apoptosis module (CASP3) included 9 genes mainly associated with protein synthesis and degradation, as well as cellular assembly and movement.
  • Table 6 represents number of genes associated with each prototype .
  • chemokine IL8 which has been reported to have pro-angiogenic effects, was indeed associated with the expression of VEGF.
  • PLAU apoptosis-related genes BCL2A1, BIRC3, CD2 and CD69 were not integrated in the apoptosis module, as their expression was also associated with ER (ESRl) .
  • ESRl ER
  • additional metalloproteases were found to be associated with PLAU, such as MMPl and MMP9, but as their expression levels were also correlated with ER (ESRl) and STATl, they were not included in the invasion module.
  • Table 7 represents clinico-pathological characteristics per molecular subgroup for the untreated breast cancer patients considered for the survival analyses.
  • Supplementary Table 2 refers to the following four tables : meta-estimators of pair-wise Pearson' s correlation coefficients between module scores of 2180 treated and untreated breast cancer patients from the global population
  • the inventors further sought to characterize the association between the module scores and the well established clinico-pathological parameters such age, tumor size, nodal status, histological grade and ER (ESRl) status defined either by immunohistochemistry (IHC) or by ligand binding assay. Meaningful associations were found, establishing the validity of module scores. For instance, highly significant associations were observed between ER
  • ESRl /proliferation module scores
  • ER ER protein status/histological grade.
  • the inventors also noticed less known or new associations, such as for example a positive association between histological grade and the angiogenesis, immune response and apoptosis module values. The same associations were also reported for nodal involvement. However, the inventors did not observe any association between the invasion module values and the clinico-pathological markers. When investigating these associations in the different molecular subgroups, the inventors found similar associations in the ESR1+/ERBB2- subgroup, with one major difference being the highly significant correlation between the ERRBB2 module scores and the histological grade which was not observed in the global population. On the contrary, very few significant associations were reported in the two other subgroups. These results are summarized in Supplementary Table 3 (se below) .
  • Supplementary Table 3 refers to the following four tables : association between the module scores and the clinico- pathological parameters for the global population (A) , ESR1-/ERBB2 (B) , ERBB2+ (C) and ESR1+/ERBB2- (D) subgroups.
  • the "+” sign represents a positive association between the variables with a p-value comprised between .01 and .05 (+) , between .01 and .001 ( ++ ) ans ⁇ .001 (+++ ) .
  • the "-" sign represents a negative association between the variables with a p-value comprised between .01 and .05 (-) , between .01 and .001 ( — )
  • Table 8 represents dissection of the gene expression prognostic signatures according to the seven prototypes.
  • the numbers represent the percentage of genes of each list related to or specifically associated with (value in brackets) a particular prototype.
  • GENE70 70 gene signature
  • the inventors then went a step further by comparing the prognostic value of each molecular module of the "dissected" signature with the original one for three of the above reported prognostic gene signatures: the 70 gene [10,4], the 76 gene [16,17] and the genomic grade [9] .
  • the inventors used the TRANSBIG independent validation series of untreated primary breast cancer patients on which these signatures were computed using the original algorithms and micro-array platforms [5, 26], providing also the advantage that this population was not used for the development of any of these signatures.
  • the inventors compared the hazard ratios for distant metastasis free survival for the group of genes from the original signatures, which were specifically associated with one of the prototypes, with the hazard ratio obtained with the original ones. Interestingly, as shown in Figure 8, the performances of the proliferation modules were equivalent to the original signatures for all three investigated signatures, suggesting that proliferation might be the driving force.
  • CDlO and/or PLAU signatures as in Tables 13 and/or 12 correlate with resistance to chemotherapy (anthracyclin) .
  • the inventors use CDlO and/or PLAU signatures as diagnosis and/or to assist the choice of suitable medicine .
  • the inventors In order to investigate which molecular subtype of breast cancer may benefit from these prognostic signatures the inventors analyzed the prognostic impact of the different gene signatures reported above in the different molecular subgroups defined by the ER (ESRl) and HER2 (ERBB2) molecular module scores. Since the exact algorithms for generating the different gene signatures cannot be applied on different micro-array platforms, the inventors decided to compute the classifiers as done for the module scores, using the direction of the association reported in the respective initial publications. Being concerned by the fact that a signed average might be less efficient than the original algorithm, the inventors conducted some comparison studies on original publications and found that the original and modified scores were highly correlated and that their performances were very similar.
  • myo-fibroblast cells (CDlO) were isolated and purified from 28 breast tumors and 4 normal tissues. Gene expression analysis was performed using the Affymetrix GeneChip® Human Genome U133 Plus 2.0 arrays. Survival analysis was carried out using 12 publicly available micro-array datasets including more than 1200 systemically untreated breast cancer patients. [0094] Breast tumor myo-fibroblast stroma cells showed an altered gene expression patterns to the ones isolated from normal breast tissues (see Tables 12 and 13) . While some of the differentially expressed genes are found to be associated with extracellular matrix formation/degradation and angiogenesis, the function of several other genes remains largely unknown.
  • the inventors first identified seven lists of genes representing the molecular modules.
  • the module comprising the highest number of genes was the ER (ESRl) module (468 genes) . This was not surprising since several publications on the molecular classification of breast cancer have repeatedly and consistently identified the oestrogen receptor status of breast cancer as the main discriminator of expression subgroups [27, 28, 29, 30] .
  • the second list with the highest number of genes was the one related to proliferation module (228 genes), which is consistent with the findings reported previously by Sotiriou et al . [30] .
  • the modules reflecting angiogenesis, apoptosis and HER2 (ERBB2) signalling only ended up with a very limited number of genes, 13, 9 and 27 genes respectively. This can be partially explained by the fact that many genes associated with these modules were also associated with ER (ESRl) or proliferation (AURKA) and therefore not retained in the development of the other molecular modules.
  • ESRl ESRl status
  • ERBB2 HER2
  • ESRl HER2
  • IFN- ⁇ enhances the immunogenicity of tumor cells in part through enhancing STATl-dependent expression of MHC proteins [46] .
  • Lynch et al recently postulated that enhancing gene transcription mediated by STATl may be an effective approach to cancer therapy [47] . Therefore, they screened 5,120 compounds and identified one molecule, 2- (1, 8-naphthyridin-2-yl) phenol, that enhanced gene activation mediated by STATl more, so that seen with maximally efficacious concentration of IFN.
  • proliferation-related genes appear to be a common denominator of several existing prognostic gene expression signatures. Since defects in cell cycle deregulation are a fundamental characteristic of breast cancer, it is not surprising that these genes are involved in breast cancer prognosis (prognostic) . Several studies showed indeed that increased expression of cell-cycle and proliferation- associated genes was correlated with poor outcome (reviewed in [48]) . There are of course differences in the exact proliferation-associated genes, due to the difference in population analyzed or platform used.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La présente invention concerne un ensemble de gènes ou de protéines comprenant ou constitué d'au moins 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, et éventuellement de 100, 105, 110 gènes ou protéines ou de l'ensemble entier sélectionné dans le tableau 10 et/ou le tableau 11 ou d'anticorps ou de partie hypervariable de cet ensemble) dirigés contre les protéines codées par ces gènes.
PCT/EP2008/061828 2007-09-07 2008-09-05 Procédés et outils de diagnostic de cancer chez des patients er- WO2009030770A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2696947A CA2696947A1 (fr) 2007-09-07 2008-09-05 Procedes et outils de diagnostic de cancer chez des patients er-
EP08803797A EP2185728A2 (fr) 2007-09-07 2008-09-05 Procédés et outils de diagnostic de cancer chez des patients er-
JP2010523521A JP2010537659A (ja) 2007-09-07 2008-09-05 Ｅｒ−患者におけるガンの予後判定のための方法およびツール
US12/733,574 US20100298160A1 (en) 2007-09-07 2008-09-05 Method and tools for prognosis of cancer in er-patients
AU2008294687A AU2008294687A1 (en) 2007-09-07 2008-09-05 Methods and tools for prognosis of cancer in ER- patients
BRPI0815460A BRPI0815460A2 (pt) 2007-09-07 2008-09-05 kit de diagnóstico ou dispositivo e método para prognóstico de cancro em sujeitos mamíferos

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97074307P 2007-09-07 2007-09-07
US60/970,743 2007-09-07

Publications (2)

Publication Number Publication Date
WO2009030770A2 true WO2009030770A2 (fr) 2009-03-12
WO2009030770A3 WO2009030770A3 (fr) 2009-05-07

Family

ID=40076838

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/061828 WO2009030770A2 (fr) 2007-09-07 2008-09-05 Procédés et outils de diagnostic de cancer chez des patients er-

Country Status (7)

Country Link
US (1) US20100298160A1 (fr)
EP (1) EP2185728A2 (fr)
JP (1) JP2010537659A (fr)
AU (1) AU2008294687A1 (fr)
BR (1) BRPI0815460A2 (fr)
CA (1) CA2696947A1 (fr)
WO (1) WO2009030770A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2203571A1 (fr) * 2007-10-30 2010-07-07 Université Libre de Bruxelles Pronostic algorithmique de cancer basé sur les gènes et résultat clinique d'un patient
WO2010118782A1 (fr) * 2009-04-17 2010-10-21 Universite Libre De Bruxelles Procédés et outils pour prédire l'efficacité d'anthracyclines dans le traitement du cancer
AU2010268389B2 (en) * 2009-07-02 2014-09-11 Embl European Molecular Biology Laboratory Diagnostic method for predicting the risk of cancer recurrence based on histone macroH2A isoforms
DE102020203224A1 (de) 2020-03-12 2021-09-16 Heinrich-Heine-Universität Düsseldorf Inhibition von FKBP1A zur Therapie des Triple-negativen Mammakarzinoms
WO2021180840A1 (fr) 2020-03-12 2021-09-16 Heinrich-Heine-Universität Düsseldorf Inhibition de fkbp1a pour la thérapie du carcinome mammaire triple négatif

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2649204A4 (fr) * 2010-12-06 2014-05-21 Univ New Jersey Med Nouvelle méthode de diagnostic et de pronostic du cancer et prédiction de la réponse à une thérapie
WO2015117204A1 (fr) * 2014-02-06 2015-08-13 Immunexpress Pty Ltd Procédé de signature de biomarqueurs, et appareil et kits associés
JP7304030B2 (ja) * 2019-04-26 2023-07-06 国立大学法人 東京大学 がん治療の効果および予後の予測方法および治療手段の選択方法
CN113025716A (zh) * 2021-03-02 2021-06-25 北京大学第一医院 一种用于人肿瘤分级的基因组合及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119593A1 (fr) 2005-05-13 2006-11-16 Universite Libre De Bruxelles Pronostic algorithmique du cancer base sur les genes gene-based algorithmic cancer prognosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0323225D0 (en) * 2003-10-03 2003-11-05 Ncc Technology Ventures Pte Lt Materials and methods relating to breast cancer classification
CA2580795A1 (fr) * 2004-09-22 2006-04-06 Tripath Imaging, Inc. Methodes et compositions permettant d'evaluer un pronostic de cancer du sein
US20080275652A1 (en) * 2005-05-13 2008-11-06 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
US20070218512A1 (en) * 2006-02-28 2007-09-20 Alex Strongin Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119593A1 (fr) 2005-05-13 2006-11-16 Universite Libre De Bruxelles Pronostic algorithmique du cancer base sur les genes gene-based algorithmic cancer prognosis

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2203571A1 (fr) * 2007-10-30 2010-07-07 Université Libre de Bruxelles Pronostic algorithmique de cancer basé sur les gènes et résultat clinique d'un patient
WO2010118782A1 (fr) * 2009-04-17 2010-10-21 Universite Libre De Bruxelles Procédés et outils pour prédire l'efficacité d'anthracyclines dans le traitement du cancer
WO2010119133A1 (fr) 2009-04-17 2010-10-21 Universite Libre De Bruxelles Procédés et outils pour prédire l'efficacité d'anthracyclines dans un cancer
AU2010268389B2 (en) * 2009-07-02 2014-09-11 Embl European Molecular Biology Laboratory Diagnostic method for predicting the risk of cancer recurrence based on histone macroH2A isoforms
DE102020203224A1 (de) 2020-03-12 2021-09-16 Heinrich-Heine-Universität Düsseldorf Inhibition von FKBP1A zur Therapie des Triple-negativen Mammakarzinoms
WO2021180840A1 (fr) 2020-03-12 2021-09-16 Heinrich-Heine-Universität Düsseldorf Inhibition de fkbp1a pour la thérapie du carcinome mammaire triple négatif

Also Published As

Publication number Publication date
WO2009030770A3 (fr) 2009-05-07
BRPI0815460A2 (pt) 2019-02-26
JP2010537659A (ja) 2010-12-09
AU2008294687A1 (en) 2009-03-12
CA2696947A1 (fr) 2009-03-12
EP2185728A2 (fr) 2010-05-19
US20100298160A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
AU2012260785B2 (en) Biomarkers for lung cancer
EP2185728A2 (fr) Procédés et outils de diagnostic de cancer chez des patients er-
KR20140105836A (ko) 다유전자 바이오마커의 확인
US20100167939A1 (en) Multigene assay to predict outcome in an individual with glioblastoma
EP2646577A2 (fr) Procédés et systèmes pour l'évaluation de la sensibilité ou de la résistance des échantillons tumoraux vis-à-vis d'agents chimio-thérapeutiques
CN113462776B (zh) m6A修饰相关联合基因组在预测肾透明细胞癌患者免疫治疗疗效中的应用
Kim et al. Promoter hypomethylation of the N-acetyltransferase 1 gene in breast cancer
EP2188385A2 (fr) Procédés et outils de diagnostic de cancer chez des patients her2+
US9347088B2 (en) Molecular signature of liver tumor grade and use to evaluate prognosis and therapeutic regimen
EP2780476B1 (fr) Méthodes de diagnostic et/ou de pronostic d'un cancer gynécologique
WO2018127786A1 (fr) Compositions et méthodes permettant de déterminer un plan d'action thérapeutique
US9195796B2 (en) Malignancy-risk signature from histologically normal breast tissue
WO2015154715A1 (fr) Procédé de diagnostic, de pronostic ou de traitement d'un cancer
TW201827603A (zh) 用於膀胱癌預後的生物標記物組合
US9708666B2 (en) Prognostic molecular signature of sarcomas, and uses thereof
WO2020174211A1 (fr) Carcinome ovarien séreux de haut grade (hgsoc)
EP2138589A1 (fr) Signature moléculaire de degré de tumeur du foie et utilisation pour évaluer le pronostic et le régime thérapeutique
JP5963748B2 (ja) 中枢神経原発悪性リンパ腫患者の予後予測方法、キット及び使用
Woodward Cell Gene Expression Signatures in Inflammatory Breast Cancer
JP2013183725A (ja) 遺伝子発現解析による大腸がんの病型分類に基づく抗癌剤応答性及び予後の予測方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08803797

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008294687

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2696947

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2008803797

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008803797

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 204282

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2010523521

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12733574

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008294687

Country of ref document: AU

Date of ref document: 20080905

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0815460

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100308